Multiple Sclerosis - New Rebif Formulation Submitted In USA And Europe (Medical News Today)
Serono (virt-x:SEO and NYSE: SRA) announced today the submission of a supplemental Biologics Licence Application (sBLA) to the US Food and Drug Administration (FDA) and of a variation to the current Marketing Authorization to the European Medicines Agency (EMEA) for a new formulation of Rebif (interferon beta-1a) as a treatment of multiple sclerosis (MS)... click link for more info.